Cure8 trial brief
Dietary strategies like the Mediterranean diet and time-restricted feeding could be low-risk ways to influence gut microbiota, short-chain fatty acids, and inflammation in people with ulcerative colitis; this trial will test those effects in remission.
Adults with ulcerative colitis in remission, clinicians and dietitians managing IBD, and researchers studying diet–microbiome interactions or dietary interventions in IBD.
This is a small, randomized interventional study (n=45) recruiting in Chile. Participants are randomized 1:1:1 to Mediterranean diet alone, Mediterranean diet plus 16:8 time-restricted feeding (eating 12:00–20:00), or standard dietary advice.
The trial’s primary outcome is change in fecal short-chain fatty acids (SCFAs) from baseline to 12 weeks; secondary outcomes include fecal calprotectin, C-reactive protein, gastrointestinal symptoms, and quality-of-life questionnaires. Study procedures include individualized isocaloric diet plans and assessments at baseline, 6 weeks, and 12 weeks.
Eligibility focuses on adults 18–60 with UC in clinical remission for at least six months and recent fecal calprotectin <250 µg/g. What this is not: This is a pilot trial protocol/registry entry, not results.
It can generate preliminary feasibility and biomarker data to support larger studies, but it does not provide evidence that these dietary approaches improve clinical outcomes yet.
This entry is a clinicaltrials.gov registry record for a recruiting pilot randomized trial; it describes planned interventions and outcomes but does not report results. The primary outcome is a biomarker (fecal SCFAs) rather than clinical endpoints.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
